Experimental cocktail aims to reboot immune attack on resistant tumors
NCT ID NCT04879849
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested an experimental drug called TAK-676 combined with the immunotherapy pembrolizumab after radiation therapy in 34 adults with advanced lung, breast, or head/neck cancers that had stopped responding to checkpoint inhibitors. The main goals were to check safety, side effects, and find the best dose of TAK-676. Participants received radiation first, then the drug combo every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-676 (an experimental drug) combined with pembrolizumab (an immunotherapy) after radiation therapy
- What this could lead to
- If successful, this could point toward a new treatment option for people with certain advanced cancers that have stopped responding to standard immunotherapy.
- What could go wrong
- This is a very early, small Phase 1 study focused on safety and dosing, not effectiveness. The combination may cause significant side effects and may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars Sinai Medical Center
Duarte, California, 91010-3012, United States
-
Laura And Isaac Perlmutter Cancer Center
New York, New York, 10016-4744, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213-2933, United States
-
University of Chicago
Chicago, Illinois, 60637-1443, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-0021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Smartphone app aims to combat malnutrition in head and neck cancer patients
- Can adding radiation boost immunotherapy against spread head and neck cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can an oral chemo pill boost immunotherapy's power against lung cancer?
- Can an immunotherapy cocktail shrink inoperable lung tumors?